Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5182269 | 0.94 | MEN1 (0.50) | MEN1KMT2ANTSR1MAPTADORA3 | |
| SCHEMBL3361558 | 0.82 | ALOX5 (0.50) | MEN1KMT2ANTSR1MAPTBCL2L1 | |
| SCHEMBL7847821 | 0.82 | NR1H4 (0.51) | MEN1KMT2ANTSR1MAPTABCG2 | |
| SCHEMBL13665827 | 0.82 | MEN1 (0.76) | MEN1KMT2ANTSR1MAPTMMP3 | |
| SCHEMBL7127169 | 0.82 | MEN1 (0.76) | MEN1KMT2ANTSR1MAPTMMP3 | |
| SCHEMBL19640929 | 0.80 | MEN1 (0.73) | MEN1KMT2ANTSR1MAPTMMP3 | |
| SCHEMBL3358276 | 0.77 | TSHR (0.47) | MEN1KMT2ANTSR1MAPTGAA | |
| SCHEMBL3359431 | 0.77 | TSHR (0.47) | MEN1KMT2ANTSR1MAPTGAA | |
| SCHEMBL20220156 | 0.75 | MEN1 (1.00) | MEN1KMT2ANTSR1MAPTMMP3 | |
| SCHEMBL22147351 | 0.74 | MMP3 (0.78) | MEN1KMT2ANTSR1MAPTMMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| US-10851079-B2 | Piperidine derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3421454-A1 | PIPERIDINE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-02 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-7572928-B2 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20090111832-A1 | Imidazolidinone Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1951709-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070142632-A1 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| WO-2007058862-A2 | IMIDAZOLIDINONE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-7173059-B2 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| EP-1633704-A2 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME | PFIZER INC. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050250949-A1 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | AGOURON PHARMACEUTICALS INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2004099129-A2 | INTERMEDIATES USEFUL IN THE SYNTHESIS OF HIV-PROTEASE INHIBITORS AND METHODS FOR PREPARING THE SAME | PFIZER INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | MEN1 2793/4885KMT2A 2525/4885NTSR1 2385/4885 |
| US-20090111832-A1 | Imidazolidinone Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease | BACE1, BACE2, PSEN1 | MEN1 1582/4885KMT2A 2284/4885NTSR1 3469/4885 |
| US-20070142632-A1 | Fluorination process | CYP2F1, SF3A2, SF3B2 | MEN1 3117/4885KMT2A 3293/4885NTSR1 4713/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | MEN1 2793/4885KMT2A 2525/4885NTSR1 2385/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | MEN1 2793/4885KMT2A 2525/4885NTSR1 2385/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | MEN1 2793/4885KMT2A 2525/4885NTSR1 2385/4885 |
| US-20050250949-A1 | Intermediates useful in the synthesis of HIV-protease inhibitors and methods for preparing the same | PEPD, DNPEP, PREP | MEN1 3629/4885KMT2A 3645/4885NTSR1 4440/4885 |
| US-10851079-B2 | Piperidine derivative | EP300, SLC11A2, TBC1D5 | MEN1 3717/4885KMT2A 1201/4885NTSR1 1707/4885 |
| US-20190040039-A1 | PIPERIDINE DERIVATIVE | EP300, SLC11A2, TBC1D5 | MEN1 3717/4885KMT2A 1201/4885NTSR1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.